Technical Insights on Biotech Stocks -- Celsion, Corcept Therapeutics, ContraVir Pharma, and Neuralstem

Wednesday, October 25, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 25, 2017 /PRNewswire/ --

If you want a Stock Review on CLSN, CORT, CTRV, or CUR then come over

to and sign up for your free customized report. On Tuesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.18%; the Dow Jones Industrial Average edged 0.72%
higher; and the S&P 500 was up 0.16%. US markets made broad based gains with six out of nine sectors finishing the day in green. Pre-market today, reviews these four Biotechnology stocks: Celsion Corp. (NASDAQ: CLSN), Corcept Therapeutics Inc. (NASDAQ: CORT), ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV), and Neuralstem Inc. (NASDAQ: CUR). Access's free research reports for this morning's stocks line-up at:


Lawrenceville, New Jersey headquartered Celsion Corp.'s stock finished Tuesday's session 0.29% higher at $3.42. A total volume of 599,532 shares was traded. The Company's shares have advanced 111.11% in the past month and 90.00% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 51.58% and 9.64%, respectively. Furthermore, shares of Celsion, which focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer, have a Relative Strength Index (RSI) of 51.57.

On October 04th, 2017, research firm Maxim Group upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $7 per share. Free research report on CLSN is available at:

Corcept Therapeutics 

Shares in Menlo Park, California headquartered Corcept Therapeutics Inc. ended at $18.99, down 0.52% from the last trading session. The stock recorded a trading volume of 1.22 million shares. The Company's shares have gained 55.66% over the previous three months, 170.90% in the last twelve months, and 161.57% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.65% and 55.36%, respectively. Moreover, shares of Corcept Therapeutics, which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have an RSI of 55.21. The complimentary research report on CORT can be downloaded at:

ContraVir Pharmaceuticals 

Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc.'s stock ended yesterday's session 7.69% lower at $0.60 with a total trading volume of 1.15 million shares, which was above its three months average volume of 1.14 million shares. The Company's shares have advanced 20.00% in the past month. The stock is trading above its 50-day moving average by 6.36%. Additionally, shares of ContraVir Pharma, which operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus infections, have an RSI of 47.11. Visit us today and access our complete research report on CTRV at:


On Tuesday, shares in Germantown, Maryland headquartered Neuralstem Inc. recorded a trading volume of 284,542 shares. The stock finished the day 1.46% higher at $1.39. The Company's shares have advanced 2.21% in the last one month. The stock is trading above its 50-day moving average by 11.30%. Furthermore, shares of Neuralstem, which focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds, have an RSI of 56.31. Get free access to your research report on CUR at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store